Swedish pharmaceutical company LIDDS has appointed Nina Herne as its new CEO. LIDDS has developed a drug delivery technology, NanoZolid, which provides a controlled and sustained release of active drug substances for up to six months. The GMP manufacturing process is based on nano-crystallizationAlready a subscriber Login You have read…